
The company reported lower PPIX levels and more pain-free light exposure, and plans a new FDA submission by year-end.
Disc Medicine plans to resubmit bitopertin for FDA approval by the end of 2026 after the drug met all primary and secondary goals in the Phase 3 APOLLO study. The company also announced a $350 million public stock placement to fund preparations for a potential launch and other pipeline projects.
Bitopertin reduced blood levels of PPIX by 41.4% compared with placebo. In the study’s sixth month, patients gained 12.2 hours of pain-free light exposure per month versus the control group.
Disc Medicine is targeting an FDA decision by mid-2027. As of Monday’s close, its shares traded at $78.93, up 38.86% from the previous close.
This article was produced with the help of AI technology. Based on reporting by the outlets listed above.